Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry.


Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
14 Feb 2019
Historique:
received: 14 06 2018
accepted: 16 01 2019
entrez: 16 2 2019
pubmed: 16 2 2019
medline: 29 5 2019
Statut: epublish

Résumé

Hypophosphatasia (HPP) is a rare, systemic disease caused by mutation(s) within the ALPL gene encoding tissue-nonspecific alkaline phosphatase (ALP). HPP has a heterogeneous presentation, which coupled with its rarity, often leads to missed/delayed diagnosis and an incomplete understanding of its natural history. To better understand the epidemiology and clinical course of HPP, including timing of diagnosis after first reported manifestation, we present baseline data for patients enrolled in the Global HPP Registry. Data were analyzed from patients with an HPP diagnosis confirmed by low serum ALP activity and/or an ALPL pathogenic variant, regardless of prior or current treatment, according to age at enrollment (children: < 18 y; adult: ≥18 y). All analyses were descriptive. Of 269 patients from 11 countries enrolled January 2015-September 2017, 121 (45.0%) were children and 148 (55.0%) were adults. The majority of children and adults were female (61.2 and 73.0%, respectively) and white (57.7 and 90.0%, respectively). Children had a median (min, max) age at earliest reported HPP manifestation of 7.2 months (- 2.3 mo, 16.0 y), which was > 12 months before diagnosis at age 20.4 months (- 0.2 mo, 16.0 y). In adults, the earliest reported manifestation occurred at a median (min, max) age of 37.6 years (0.2 y, 75.2 y), which preceded age at diagnosis (47.5 years [0.2 y, 75.2 y]) by ~ 10 years. Premature loss of deciduous teeth (48.2%, age ≥ 6 mo), bone deformity (32.5%), and failure to thrive (26.7%) were most commonly reported in the HPP-related disease history of children. Pain (74.5%), orthopedic procedures and therapies (44.6%), and recurrent and poorly healing fractures (36.5%) were most commonly reported in the HPP-related disease history of adults. The Global HPP Registry represents the largest observational study of patients with HPP, capturing real world data. This analysis shows that diagnostic delay is common, reflecting limited awareness of HPP, and that HPP is associated with systemic manifestations across all ages. Many patients diagnosed in adulthood had HPP manifestations in childhood, highlighting the importance of taking thorough medical histories to ensure timely diagnosis. Clinicaltrials.gov : NCT02306720 , December 2014; ENCePP.eu: EUPAS13526 , May 2016 (retrospectively registered).

Sections du résumé

BACKGROUND BACKGROUND
Hypophosphatasia (HPP) is a rare, systemic disease caused by mutation(s) within the ALPL gene encoding tissue-nonspecific alkaline phosphatase (ALP). HPP has a heterogeneous presentation, which coupled with its rarity, often leads to missed/delayed diagnosis and an incomplete understanding of its natural history. To better understand the epidemiology and clinical course of HPP, including timing of diagnosis after first reported manifestation, we present baseline data for patients enrolled in the Global HPP Registry.
METHODS METHODS
Data were analyzed from patients with an HPP diagnosis confirmed by low serum ALP activity and/or an ALPL pathogenic variant, regardless of prior or current treatment, according to age at enrollment (children: < 18 y; adult: ≥18 y). All analyses were descriptive.
RESULTS RESULTS
Of 269 patients from 11 countries enrolled January 2015-September 2017, 121 (45.0%) were children and 148 (55.0%) were adults. The majority of children and adults were female (61.2 and 73.0%, respectively) and white (57.7 and 90.0%, respectively). Children had a median (min, max) age at earliest reported HPP manifestation of 7.2 months (- 2.3 mo, 16.0 y), which was > 12 months before diagnosis at age 20.4 months (- 0.2 mo, 16.0 y). In adults, the earliest reported manifestation occurred at a median (min, max) age of 37.6 years (0.2 y, 75.2 y), which preceded age at diagnosis (47.5 years [0.2 y, 75.2 y]) by ~ 10 years. Premature loss of deciduous teeth (48.2%, age ≥ 6 mo), bone deformity (32.5%), and failure to thrive (26.7%) were most commonly reported in the HPP-related disease history of children. Pain (74.5%), orthopedic procedures and therapies (44.6%), and recurrent and poorly healing fractures (36.5%) were most commonly reported in the HPP-related disease history of adults.
CONCLUSIONS CONCLUSIONS
The Global HPP Registry represents the largest observational study of patients with HPP, capturing real world data. This analysis shows that diagnostic delay is common, reflecting limited awareness of HPP, and that HPP is associated with systemic manifestations across all ages. Many patients diagnosed in adulthood had HPP manifestations in childhood, highlighting the importance of taking thorough medical histories to ensure timely diagnosis.
TRIAL REGISTRATION BACKGROUND
Clinicaltrials.gov : NCT02306720 , December 2014; ENCePP.eu: EUPAS13526 , May 2016 (retrospectively registered).

Identifiants

pubmed: 30764793
doi: 10.1186/s12891-019-2420-8
pii: 10.1186/s12891-019-2420-8
pmc: PMC6376686
doi:

Substances chimiques

ALPL protein, human EC 3.1.3.1
Alkaline Phosphatase EC 3.1.3.1

Banques de données

ClinicalTrials.gov
['NCT02306720']

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Références

Acad Emerg Med. 2002 Jun;9(6):609-12
pubmed: 12045074
Am J Med. 1957 May;22(5):730-46
pubmed: 13410963
Lancet. 1965 Sep 4;2(7410):461-4
pubmed: 14337825
Biol Trace Elem Res. 2005 May;104(2):131-40
pubmed: 15894813
J Pediatr. 2005 Sep;147(3 Suppl):S30-6
pubmed: 16202779
Am J Hum Genet. 1990 Feb;46(2):286-92
pubmed: 1689104
J Bone Miner Res. 2009 Jun;24(6):1132-4
pubmed: 19113923
J Paediatr Child Health. 2009 Apr;45(4):199-203
pubmed: 19426378
Ann N Y Acad Sci. 2010 Mar;1192:190-200
pubmed: 20392236
J Hum Genet. 2011 Feb;56(2):166-8
pubmed: 21179104
Ann Hum Genet. 2011 May;75(3):439-45
pubmed: 21488855
J Bone Miner Res. 2012 May;27(5):987-94
pubmed: 22322541
Physiother Res Int. 2013 Dec;18(4):203-11
pubmed: 23281201
Bone. 2013 May;54(1):21-7
pubmed: 23352924
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8
pubmed: 23858621
Arch Dis Child. 2014 Mar;99(3):211-5
pubmed: 24276437
Eur J Hum Genet. 2014 Oct;22(10):1160-4
pubmed: 24569605
Health Qual Life Outcomes. 2014 Apr 16;12:54
pubmed: 24742068
Paediatr Anaesth. 2014 Nov;24(11):1127-31
pubmed: 25074484
J Bone Miner Res. 2015 Sep;30(9):1726-37
pubmed: 25736332
Am J Med Genet A. 2016 Jan;170A(1):62-76
pubmed: 26365089
Clin Cases Miner Bone Metab. 2015 May-Aug;12(2):170-3
pubmed: 26604944
Nat Rev Endocrinol. 2016 Apr;12(4):233-46
pubmed: 26893260
Metabolism. 2016 Oct;65(10):1522-30
pubmed: 27621187
JCI Insight. 2016 Jun 16;1(9):e85971
pubmed: 27699270
Emerg Med J. 2017 Mar;34(3):138-144
pubmed: 27797872
Bone Rep. 2016 Aug 26;5:228-232
pubmed: 28580391
Mol Genet Metab. 2017 Sep;122(1-2):4-17
pubmed: 28888853
Arch Dis Child. 2018 Jul;103(7):648-653
pubmed: 29104181
J Bone Miner Metab. 2018 Nov;36(6):723-733
pubmed: 29236161
Osteoporos Int. 2018 Aug;29(8):1815-1825
pubmed: 29774402
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7666-9
pubmed: 3174660
J Clin Invest. 1985 Aug;76(2):752-6
pubmed: 4031070

Auteurs

Wolfgang Högler (W)

Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.

Craig Langman (C)

Feinberg School of Medicine, Northwestern University and Lurie Children's Hospital, Chicago, IL, USA.

Hugo Gomes da Silva (H)

Alexion Pharmaceuticals, Inc., Boston, MA, USA.

Shona Fang (S)

Alexion Pharmaceuticals, Inc., Boston, MA, USA.

Agnès Linglart (A)

APHP, Bicêtre Paris-Sud, University Paris Sud, Paris-Saclay, Le Kremlin Bicêtre, Paris, France.

Keiichi Ozono (K)

Department of Pediatrics, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan.

Anna Petryk (A)

Alexion Pharmaceuticals, Inc., Boston, MA, USA.

Cheryl Rockman-Greenberg (C)

Rady Faculty of Health Sciences, Max Rady College of Medicine, and Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.

Lothar Seefried (L)

Orthopaedic Clinic, König-Ludwig-Haus, University of Würzburg, Würzburg, Germany.

Priya S Kishnani (PS)

Department of Pediatrics, Duke University Medical Center, 2301 Erwin Rd, Durham, NC, 27710, USA. priya.kishnani@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH